12/13
08:31 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
High
Report
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Piper Sandler from $28.00 to $42.00. They now have an "overweight" rating on the stock.
12/2
06:11 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock, up previously from $24.00.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock, up previously from $24.00.
12/2
12:19 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock, up previously from $30.00.
Medium
Report
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock, up previously from $30.00.
12/2
07:08 am
nvcr
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $30.00 price target on the stock, up previously from $18.00.
High
Report
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $30.00 price target on the stock, up previously from $18.00.
12/2
07:00 am
nvcr
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
High
Report
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
11/27
07:00 am
nvcr
Novocure to Participate in Upcoming Investor Conferences
High
Report
Novocure to Participate in Upcoming Investor Conferences
11/21
01:46 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/21
07:07 am
nvcr
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]
Medium
Report
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]
11/21
07:05 am
nvcr
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Low
Report
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
11/21
07:00 am
nvcr
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
Low
Report
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
10/31
08:35 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
10/30
07:02 am
nvcr
Novocure Appoints Christoph Brackmann as Chief Financial Officer
Medium
Report
Novocure Appoints Christoph Brackmann as Chief Financial Officer
10/30
07:00 am
nvcr
Novocure Reports Third Quarter 2024 Financial Results
Low
Report
Novocure Reports Third Quarter 2024 Financial Results
10/16
11:01 am
nvcr
NovoCure: There Is Still More Upside [Seeking Alpha]
Low
Report
NovoCure: There Is Still More Upside [Seeking Alpha]
10/16
07:39 am
nvcr
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $30.00 price target on the stock, up previously from $24.00.
High
Report
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $30.00 price target on the stock, up previously from $24.00.
10/15
04:43 pm
nvcr
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
High
Report
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer